Production (Stage)
Ginkgo Bioworks Holdings, Inc.
DNA
$7.25
-$0.17-2.29%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 44.71% | 38.73% | 23.98% | 26.65% | 50.34% |
| Total Depreciation and Amortization | 1.71% | -10.62% | -19.95% | 3.28% | 18.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -51.50% | -48.88% | -33.44% | -42.71% | -65.79% |
| Change in Net Operating Assets | -454.30% | -400.53% | -146.77% | 99.72% | 232.53% |
| Cash from Operations | 4.19% | -8.15% | 2.11% | -2.70% | 8.89% |
| Capital Expenditure | -126.05% | -53.28% | 17.02% | 42.34% | 58.80% |
| Sale of Property, Plant, and Equipment | -85.37% | -85.37% | -30.14% | -40.58% | 7,734.48% |
| Cash Acquisitions | 100.00% | -- | -107.23% | -107.23% | -107.23% |
| Divestitures | -- | -- | -- | -51.40% | -59.49% |
| Other Investing Activities | -13,506.80% | 477.39% | 114.89% | 96.94% | 95.51% |
| Cash from Investing | -239.03% | 22.87% | -2,139.43% | -87.84% | -44.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 36.07% | 30.73% | 22.27% | 10.58% | 0.47% |
| Issuance of Common Stock | -90.73% | -9.68% | -99.90% | -99.85% | -99.85% |
| Repurchase of Common Stock | -- | -- | 97.66% | 97.66% | 97.82% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 85.00% | 53.49% | 43.01% | 54.37% | 20.73% |
| Cash from Financing | 65.30% | 45.93% | -102.28% | -102.12% | -103.32% |
| Foreign Exchange rate Adjustments | 93.05% | 52.21% | -125.92% | -151.45% | -180.79% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -43.17% | -1.01% | -72.62% | -59.31% | -34.01% |